Low bacterial diet versus control diet to prevent infection in cancer patient treated with chemotherapy causing episodes of neutropenia (Review)

Department of Paediatric Oncology, Emma Children’s Hospital / Academic Medical Center, Amsterdam, Netherlands.
Cochrane database of systematic reviews (Online) (Impact Factor: 6.03). 09/2012; 9(9):CD006247. DOI: 10.1002/14651858.CD006247.pub2
Source: PubMed


Neutropenia is a potentially serious side effect of chemotherapy and a major risk factor for infections, which can be life-threatening. It has been argued that a low bacterial diet (i.e. food and drinks with low levels of bacteria) can prevent the occurrence of infections and (infection-related) death in cancer patients receiving chemotherapy causing episodes of neutropenia. The review authors identified three randomised studies comparing different diets in 192 children and adults with different types of cancer. Other interventions, such as antimicrobial prophylaxis (i.e. prevention of infections using antimicrobial therapy such as antibiotics) and hygiene practices, and definitions of the different study outcomes also differed between the studies and very limited information on anticancer treatment was given. All studies had methodological problems. Unfortunately, combining the results of the included studies was not possible, but at the moment there is no evidence from individual studies showing that the use of a low bacterial diet prevents infections. Data on survival, time from onset of neutropenia to fever, the duration of empirical (i.e. the start of treatment prior to determination of a definitive diagnosis) antibiotics and antimycotics (i.e. agents that target fungal infections), diet acceptability and quality of life were all evaluated by only one study; for all outcomes no statistically significant differences between the treatment groups was observed. None of the studies evaluated infection-related mortality. It should be noted that 'no evidence of effect', as identified in this review, is not the same as 'evidence of no effect'. The reason that no difference between the different diets was identified could, for example, be the result of the low number of patients included in the studies. Based on the currently available evidence, the review authors were not able to give recommendations for clinical practice. More high-quality research is needed.

Download full-text


Available from: Edith Leclercq, Mar 27, 2015
72 Reads
  • Source
    • "During chemotherapy in patients with cancer, there is an increased risk of infections due to a low white blood cell count caused by the toxic effect of drugs on the bone marrow [44]. Bacterial infections are a major cause of morbidity and mortality in patients receiving chemotherapy for malignancy [44], [45]. In chemotherapy for MDR cancer, inhibition of ABCG2 is expected to enhance the efficacy of the anti-cancer drug treatment. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer resistance protein (ABCG2), a member of the ATP-binding cassette transporters has been identified as a major determinant of multidrug resistance (MDR) in cancer cells, but ABC transporter inhibition has limited therapeutic value in vivo. In this research, we demonstrated that inhibition of efflux transporters ABCG2 induced the generation of tolerogenic DCs from human peripheral blood myeloid DCs (mDCs). ABCG2 expression was present in mDCs and was further increased by LPS stimulation. Treatment of CD1c+ mDCs with an ABCG2 inhibitor, Ko143, during LPS stimulation caused increased production of IL-10 and decreased production of pro-inflammatory cytokines and decreased expression of CD83 and CD86. Moreover, inhibition of ABCG2 in monocyte-derived DCs (MDDCs) abrogated the up-regulation of co-stimulatory molecules and production of pro-inflammatory cytokines in these cells in response to LPS. Furthermore, CD1c+ mDCs stimulated with LPS plus Ko143 inhibited the proliferation of allogeneic and superantigen-specific syngenic CD4+ T cells and promoted expansion of CD25+FOXP3+ regulatory T (Treg) cells in an IL-10-dependent fashion. These tolerogenic effects of ABCG2 inhibition could be abolished by ERK inhibition. Thus, we demonstrated that inhibition of ABCG2 in LPS-stimulated mDCs can potently induce tolerogenic potentials in these cells, providing crucial new information that could lead to development of better strategies to combat MDR cancer.
    PLoS ONE 08/2014; 9(8):e104753. DOI:10.1371/journal.pone.0104753 · 3.23 Impact Factor

  • Clinical advances in hematology & oncology: H&O 12/2012; 10(12):825-6.

  • Cancer nursing 11/2013; 36(6):493. DOI:10.1097/NCC.0b013e31829f5449 · 1.97 Impact Factor
Show more